Dendritic cells (DC) generated from human umbilical cord blood might replace patients' DC in attempts to elicit tumor-specific immune response in cancer patients. We studied the efficiency of 
Bone marrow-derived DC are the only antigen-presenting cells able to induce the response of naive T cells (Banchereau & Steinman, 1998) . Cancer therapy based on the use of DC to present tumorassociated antigens has been shown to elicit tumorspecific immune response in humans, and resulted in clinical responses in a substantial proportion of patients (for a review, see Fong & Engleman, 2000; Schuler et al., 2003) . So far, several strategies of loading DC with tumor antigens ex vivo have been used in clinical trials. DC were pulsed with tumor proteins (Hsu et al., 1996; Timmerman et al., 2002) , tumor peptides or whole lysates of tumor cells (Nestle et al., 1998) , or fused with tumor cells (Krause et al., 2002) . However, the procedures of vaccination using DC pulsed with tumor lysates or DC-tumor cell hybridomas depend on the accessibility of autologous tumor cells, and the use of peptides for vaccination is limited by the major histocompatibility complex (MHC) restrictions and by the limited number of known tumor peptides. Therefore, regarding all the limitations, transfection of DC with DNA encoding tumor-associated proteins may become an alternative method to obtain DC that endogenously express and process tumor proteins, and present multiple tumor epitopes to CD8 + T lymphocytes in the context of MHC class I molecules.
The choice and accessibility of DC is another important issue in immunotherapy. Deficites of DC count and their defective function in cancer patients (Gabrilovich et al., 1997; Savary et al., 1998) may limit the accessibility of patients' DC for vaccination, and consequently may hamper attempts to design vaccines based on autologous DC. This problem could be potentially overcome by the use of allogeneic DC matching the patient's MHC class I haplotype. Human umbilical cord blood can be considered as a potential source of allogeneic DC for vaccination against cancer. Cord blood mononuclear cells (CBM-NC) contain a relatively high percentage of both hematopoietic stem cells and committed DC precursors which, when stimulated with GM-CSF and TNF-α, proliferate and differentiate into functionally mature DC (Caux et al., 1992; Santiago-Schwarz et al., 1992) . SCF and FL co-stimulate the generation of DC from hematopoietic progenitors induced by GM-CSF and TNF-α (Siena et al., 1995) . Differentiation of CD34 + hematopoietic progenitors into mature functional DC is also induced by stimulation with phorbol ester -PMA (Davis et al., 1998) . Cord blood DC generated in vitro are able to process soluble antigens and prime naive T cells (Caux et al., 1995; Davis et al., 1998) . This is the first study comparing two strategies of production of transfected DC: direct electroporation of differentiated DC derived from umbilical cord blood CD34 + cells, and electroporation of human umbilical cord blood hematopoetic CD34 + cells followed by their differentiation to mature DC. In the former procedure the number of transfected DC was limited because of the low efficiency of electroporation. In the latter procedure, in spite of the high efficiency of electroporation, the number of transgene-expressing mature DC was limited because the proliferation rate of transfected CD34 + cell population was lower as compared to the untransfected cells.
MATERIALS AND METHODS
Cell isolation. Cord blood samples were collected from full-term normal deliveries. CBMNC were isolated by density gradient centrifugation on Ficoll-Uropoline (density 1.077 g/ml). The CD34 + cell fraction was isolated using CD34 Direct Isolation Kit (Miltenyi Biotec), according to the manufacturer's recommendations, as previously described (Ołdak et al., 2002) .
Induction of DC growth and maturation in CBMNC cultures. CBMNC were cultured in teflon vessels in AIM V Medium containing 0.25% human serum albumin (HSA) (Life Technologies), supplemented with GM-CSF (800 U/ml; R&D Systems), SCF (20 ng/ml; R&D Systems) and FL (20 ng/ml; R&D Systems), for 3, 5 or 11 days before electroporation. After electroporation, cells were cultured in AIM V Medium supplemented with GM-CSF, SCF, FL and PMA (50 ng/ml; Sigma).
Generation of DC in cultures of isolated CD34 + cells. Isolated CD34 + cells were cultured at a cell density of 1 × 10 5 /ml for 2 days before electroporation in CellGro Stem Cell Growing Medium (SCGM) (CellGenix) for serum-free culture of hematopoietic stem and progenitor cells, supplemented with SCF (20 ng/ml), trombopoietin (TPO) (50 ng/ ml; PeproTech EC) and FL (50 ng/ml), as previously described (Ołdak et al., 2002) . After electroporation, CD34 + cells were cultured in CellGro SCGM supplemented with GM-CSF (800 U/ml), SCF (25 ng/ml) and FL (50 ng/ml). TNF-α (50 U/ml; R&D Systems) was added to the culture medium one day after electroporation.
Electroporation. Electroporation was performed in 0.4 cm gap sterile disposable cuvettes using a Gene Pulser (BioRad) or a BTX ECL600 instrument (Gentronix). CBMNC (2-4 × 10 6 ) were suspended in 250 μl AIM V Medium. Plasmid DNA (pEGFP-N; Clontech), carrying EGFP as a reporter gene under the control of the CMV promoter, was added to the cell suspension at concentrations of 40 μg/ml or 80 μg/ml chosen after preliminary testing of concentrations ranging from 8 to 80 μg/ml. Cells electroporated without the plasmid served as a control. For the CBMNC population, various combinations of the following electropulse parameters were applied: voltage: 250 V or 300 V; capacitance: 500 μF, 950 μF or 1600 μF; resistance: 48 Ω, 186 Ω, 720 Ω or ∞ Ω. Pulse length fell within the range of 31 to 63 ms.
Isolated CD34 + cells were electroporated at the parameters set previously as optimal (Ołdak et al., 2002) . CD34 + cells (2-7 × 10 5 ) were suspended in 500 μl of CellGro medium supplemented with 1% HSA. Plasmid DNA was added at a concentration of 20 μg/ml. Voltage was set at 220 V, resistance at 246 Ω and capacitance at 1600 μF.
Flow cytometric analysis. Transfection efficiency, cell viability and immunophenotype were determined by flow cytometry. Phycoerythrin (PE)-conjugated anti-CD3, -CD11b, -CD14, -CD16, -CD20, -CD34, -CD80, -CD86 or -CD83 monoclonal antibod-ies (moAbs), peridinin chlorophyll protein (PerCP)-conjugated anti-HLA-DR moAb, and PE-conjugated mouse IgG 1 and IgG 2a controls were purchased from Becton-Dickinson. Cell samples were examined in a FACSCalibur flow cytometer (Becton-Dickinson).
To identify DC and their precursors in the CBMNC population and among the cells generated from purified cord blood hematopoietic cells, cell samples were stained with a mixture of PE-conjugated moAbs recognizing CD3, CD11b, CD14, CD16, and CD20 lineage-associated molecules (lin cocktail) and HLA-DR-PerCP moAb. In a selected experiment, anti-CD34 moAb was included in the lin mixture of moAbs, to exclude CD34 + progenitors from the linnegative population in cytometric evaluation. Thirty or twenty, thousand events that fell within the gate encompassing nucleated cells were collected from immunolabelled samples of CBMNC cultured for 1, 2, 3 or 4 days post-electroporation, and of cells generated from purified CD34 + hematopoietic stem cells after 2, 5, 8, 12 or 15 days of culture post-electroporation. The absolute numbers of DC and their precursors (cells of the lin -HLA-DR + phenotype), hematopoietic CD34 + cells, and cells expressing the co-stimulatory molecule CD86 or the activation molecule CD83, were backcalculated from their proportion in CBMNC, as determined by flow cytometric analysis, and the total number of CBMNC in the culture. Cell viability of CBMNC was determined by staining with propidium iodide (PI, 0.3 μg/ml) for 30 min before flow cytometric acquisition.
RESULTS

Transfection of DC generated in CBMNC cultures
Total CBMNC population pre-cultured for 3, 5 or 11 days in the presence of GM-CSF, SCF, and FL to promote DC growth, was transfected at various electrical parameters to optimize the conditions of electroporation. After electroporation the cells were cultured in the presence of GM-CSF, SCF, FL, and PMA added to the culture to induce DC differentiation. Our preliminary experiments had shown that there was a more pronounced decrease of cell viability after electroporation at the voltage set at 300 V than at 250 V (not shown). Therefore, further experiments were performed at 250 V. Two days after electroporation the viability of CBMNC pre-cultured for 3 days before electroporation ranged from 49.3% to 88.7% (median value 79.0%, n = 7). The viability of CBMNC pre-cultured for 5 or 11 days before transfection fell within the same range. EGFP expression was found mostly in viable cells (not shown). When the capacitance was set at 950 μF, the percentage of viable CBMNC expressing the reporter gene on days 1 and 2 after electroporation ranged from 0.19% to 2.11% (n = 6) and from 0.17% to 1.61%, respectively. When the capacitance was set at 1600 μF, the percentage of EGFP + cells among viable CBMNC on days 1 and 2 after electroporation ranged from 1.80% to 2.64% (n = 3), and from 2.08% to 2.32%, respective- ly. The transfection efficiency after electroporation at the capacitance of 500 μF did not exceed 0.56% of viable CBMNC (n = 3).
The efficiency of transfection of DC generated in CBMNC cultures was determined by flow cytometry analysis of EGFP + cell content within the gate encompassing cells of the lin -HLA-DR + phenotype, as shown in Fig. 1 . The efficiency of transfection of lin -HLA-DR + cells two days after electroporation did not exceed 2.5%, and was similar to the efficiency found for total CBMNC ( (Table 1) . Cells maintaining the progenitor phenotype comprised a minor fraction (< 0.5%) of CBMNC cultured for 5 days.
Differentiation of DC expressing the reporter gene from transfected CD34 + progenitor cells
As shown here and in our previous study (Ołdak et al., 2002) , electrotransfection of DC and 
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of other subsets generated from pre-stimulated CB-MNC population resulted in a relatively low efficiency as compared to the efficiency of transfection of CD34 + hematopoietic cells. Therefore, we attempted to generate DC from transfected cord blood CD34 + cells. At first, purified CD34 + cells were cultured for 2 days in the presence of SCF, TPO, and FL, what supported the growth of progenitor cells without a loss of their pluripotency. Thereafter, the prestimulated cells were electroporated at the optimal capacitance (1600 μF) and voltage (220 V), and cultured in the presence of GM-CSF, SCF, FL, and TNF-α selectively promoting growth and differentiation of DC. Two days after electroporation, 89% of the cultured cells still expressed the CD34 marker of progenitor cells, and 44% of the cultured cells expressed the reporter gene. This means that at this time point the majority of cells of the lin -HLA-DR + phenotype belonged to the subpopulation of CD34-positive progenitor cells. During five days following electroporation, the proportion of differentiated cells expressing lineage markers increased, whereas the proportion of lin -HLA-DR + and of CD34 + HLA-DR + cells decreased ( Fig. 2A, B) . During the next three days, an increase of the absolute number of differentiated DC of the lin -HLA-DR + phenotype, lacking the CD34 marker, was accompanied by a further decrease of the CD34 + HLA-DR + cell subpopulation, due to differentiation of CD34 + progenitors in the culture. Eight days post-electroporation, the number of differentiated lin -HLA-DR + DC expressing EGFP exceeded the number of CD34 + cells expressing EGFP. Fifteen days after electroporation, the majority of EGFP-expressing cells displayed the activation molecule CD83, known as a marker of mature DC, and the co-stimulatory molecule CD86, a marker of antigen-presenting cells (Fig. 2C) . On day 15 postelectroporation, the numbers of CD86 + cells and of CD83 + cells exceeded the number of cells of the lin -HLA-DR + phenotype. Intermediate DC precursors transiently expressing the CD14 molecule might express the CD86 molecule, and a subset of DC expressing CD11b might express CD83. However, the compartment of cells identified as DC, according to the criterion of the lin -HLA-DR + phenotype, included neither intermediate CD14 + CD86 + precursors of DC nor the CD11b + CD83 + DC subset, since the lin mixture used in this study contained anti-CD14 and anti-CD11b monoclonal antibodies.
Transfected CD34 + hematopoietic cells were able to differentiate into DC, and a 7-fold expansion of total cell population was observed during 15 days of culture following electroporation with the plasmid. However, that was not accompanied by a proportional expansion of cells expressing the reporter gene. The absolute number of EGFP-expressing cells during the culture did not increase substantially over the value found two days post-electroporation. In addition, the total cell yield in the culture of mock-electroporated cells was more than one order of magnitude higher than the total cell yield in the culture of plasmid-electroporated cells (Fig. 3) . Similarly, the yield of differentiated DC in the culture of mock-electroporated cells was much higher as compared to the DC yield in the culture of plasmidelectroporated cells. This suggests that loading with plasmid DNA decreases the proliferation of CD34 + hematopoietic cells and/or increases the rate of cell death of transfected cells in culture.
DISCUSSION
Dendritic cell-based vaccination appears to be a very promising strategy of inducing anti-cancer immune response. One of the crucial issues in attempts to engineer immune response with the use of DC is efficient loading of DC with antigens. Genetic manipulation of DC is considered a method of obtaining DC able to synthesize tumor associated antigens (TAA) de novo and to present multiple MHC class I-restricted epitopes of TAA. The use of DC that process endogeneous TAA may resolve the problem of preparing a set of synthetic tumor peptides for individual cancer patient. Viral transfection has proved so far to be an efficient method of engineering human DC expressing TAA. CD34 + cell-derived DC as well as monocyte-derived DC were transduced with the use of viral vectors (Kim et al., 1997; Perez-Diez et al., 1998; Oki et al., 2001; Temme et al., 2002) . However, the risk of oncogenesis or mutagenesis resulting from the insertion of a viral genome into the host DNA and the problem of immunogenicity of viral proteins remain a serious safety concern (Ying et al., 1999) . This safety concern severely limits the use of engineered viruses in the clinical setting. Therefore, exploration of non-viral DC transfection is of high interest in the field of immunotherapy.
In this study, we report the evaluation of two alternative strategies of obtaining cord blood DC expressing a transgene. One of these strategies was based on the electrotransfection of DC generated in the culture of CBMNC supplemented with cytokines promoting DC growth and differentiation from both pluripotent hematopoietic stem cells and committed myeloid DC precursors at various stages of differentiation. Although transfected DC brightly expressed EGFP, the transfection efficiency (< 2.5%) was much lower than the transfection efficiency of a minor fraction of hematopoietic cells of the CD34 + HLA-DR -phenotype, persisting in CB-MNC culture, and, similarly, much lower than the previously reported transfection efficiency of purified hematopoietic CD34 + cells, pre-stimulated for 2 days with a cytokine mixture inducing cell proliferation without a loss of their pluripotency (Wu et al., 2001a; 2001b; Ołdak et al., 2002) . The transfection efficiency of DC generated from CBMNC progenitors, described in our study, was of a similar magnitude as the transfection efficiency of monocyte-derived DC generated from peripheral blood monocytes, reported by others (Van Tendeloo et al., 1998; Strobel et al., 2000) , but lower than the efficiency of gene transfer to DC derived from purified CD34 + hematopoietic progenitors (12%) (Van Tendeloo et al., 1998) . The proliferative potential of purified CD34 + hematopoietic progenitors is higher than that of committed myeloid DC precursors within CBMNC population, being at various stages of differentiation. This may suggest that the susceptibility to transfection of differentiating DC precursors is gradually reduced due to the gradual loss of their proliferative potential accompanying their differentiation in culture. It has been shown previously that the susceptibility to transfection with plasmid DNA depends on the proliferative potential of transfected cells. A mitogenic stimulus is required to make human peripheral blood T cells receptive for transfection (Van Tendeloo et al., 2000) . Adult bone marrow CD34 + cells stimulated to proliferate become much more receptive to gene transfer with the use of plasmid DNA than unstimulated bone marrow CD34 + cells (Van Tendeloo et al., 2000) . In addition, the ongoing process of differentiation of hematopoietic progenitor cells, in fact, may by itself affect the susceptibility of these cells to transfection, though the proportion of cells recruited to the cell cycle does not change. CD34 + cells isolated from mobilized peripheral blood of patients reach the maximal susceptibility to transfection within 24-48h in culture, but later on the susceptibility decreases, although the percentage of cells in S-phase remains stable up to 4 days (Wu et al., 2001c) . It has been shown previously that electrotransfection does not adversely affect the function of viable DC in antigen presentation. No significant impairment of the capacity of transfected DC to induce mixed lymphocyte reaction was found when DC maintained viability for a few days following electroporation (Van Tendeloo et al., 1998) . In our study the majority of transfected CBMNC were viable 2 days after transfection. The viability was maintained later in the culture, but the percentage of EGFP-expressing cells was reduced by half 4 days after transfection (not shown). Regarding cancer immunotherapy purposes, the achieved transient gene expression by DC without a substantial loss of cell viability for a few days following electroporation might be sufficient for effective antigen presentation. However, the relatively low transfection efficiency would be the main obstacle in attempts to use DC transfected with plasmid DNA for immunotherapy purposes. Although the proportion of differentiated DC is relatively high among CBMNC stimulated with cytokines promoting DC growth and differentiation, multiple cord blood preparations would be required to perform a cycle of immunization of one cancer patient with the use of allogeneic cord blood DC transfected with a plasmid carrying tumor genes. Thus, further improvement of non-viral DNA transfection is desirable to make this method competitive with other methods of loading DC with antigens.
A new method of nucleoporation with the use of Amaxa Nucleofector, described by Lenz et al. (2003) , made possible gene transfer to monocyte-derived DC with the use of plasmid DNA, with efficiencies approaching 60%, but a loss of cell viability was observed within a few hours following transfection. Such a loss of DC viability after transfection is unacceptable regarding DC application for immunotherapy purposes, since it might substantially reduce the chance of reinjected DC getting in contact with T cells and presenting antigens in vivo. Therefore the use of the method described by Lenz et al. (2003) will be limited until the cell viability is improved.
Since the efficiency of DNA transfer to differentiating DC was low, we attempted to generate DC expressing a transgene from transfected CD34 + cord blood hematopoietic cells by stimulation with a mixture of cytokines selectively promoting DC growth and differentiation. Hematopoietic CD34 + cells were transfected with high efficiency. The transfected hematopoietic progenitors preferentially differentiated into cells of the DC phenotype. Following cell differentiation the majority of EGFP + cells expressed CD83, a marker of mature DC. However, the yield of DC expressing the transgene after culture of plasmid-electroporated cells did not match the yield of expanded population of DC with undetectable EGFP expression. In addition, total cell yield and DC yield in the culture of plasmid-electroporated cells did not match the total cell yield and DC yield, respectively, in the culture of mock-electroporated cells. Thus, generation of DC from transfected CD34 + cord blood hematopoietic would provide a very limited number of transgeneexpressing DC for cancer immunotherapy. Wu et al. (2001b) found previously that during stem cell differentiation transgene expression may differ in various cell populations, and may not be sustained in more differentiated cell populations. In their study, the yield of transgene-expressing cells generated from transfected CD34 + cord blood hematopoietic cells did not match the total cell yield after 11 days of culture in IL-3-, GM-CSF-, and G-CSFsupplemented medium. They found EGFP + cells among CD33 + /CD11b + early myeloid cells, but no EGFP + cells among more differentiated populations of CD14 + monocytes and CD41a + megakaryocytes after the culture.
Comparative studies on gene delivery by mRNA electroporation and by plasmid DNA electroporation performed side-by-side have demonstrated that RNA electroporation results in a higher transfection efficiency of monocyte-or CD34 + cellderived DC and lower cytotoxicity (Strobel et al., 2000; Van Tendeloo et al., 2001; Saebøe-Larssen et al., 2002; Lundqvist et al., 2002) . RNA-transfected DC efficiently stimulate antigen-specific T cells, far better than DNA-transfected DC in side-by-side comparison (Strobel et al., 2000) . Comparative studies on plasmid DNA transfection have also demonstrated that other methods may become an alternative for electroporation. For example, efficient tranfection by immunolipoplexes (Tan et al., 2005) , cationic peptide (Irvine et al., 2000) or peptide/liposome systems (Uduehi et al., 2003) result in a higher transfection efficiency of monocyte-or CD34 + cell-derived DC, and a comparable toxicity. However, DC transfected with the use of immunolipoplexes render T cell anergic for further stimulation with antigens (Tan et al., 2005) , and therefore the method seems suitable rather for tolerance induction protocols. The rapid decline of transgene expression after transfection by the peptide/liposome system (Uduehi et al., 2003) and the toxicity of the lipid compounds may limit the applicability of lipid-based methods in clinical settings. Further development of gene delivery methods is required to achieve progress in DC-based immunotherapy.
